BACKGROUND: Angiogenesis has been implicated in the pathogenesis of idiopathic interstitial pneumonia (IIP). The aim of this study was to examine the relationship between plasma concentrations of the angiogenic cytokines interleukin 8 (IL-8), vascular endothelial growth factor (VEGF), and endothelin-1 (ET-1) and clinical parameters of disease progression over a 6 month period to identify potential aetiological mediators and prognostic markers of disease activity in patients with IIP. METHODS: Forty nine patients with IIP (40 men) were recruited to the study. Plasma cytokine measurements, pulmonary function tests, and high resolution computed tomography (HRCT) scans were performed on recruitment and after 6 months. Plasma cytokine measurements were also performed in 15 healthy volunteers for control purposes. RESULTS: Patients with IIP had significantly higher median (IQR) baseline concentrations of IL-8 and ET-1 than controls (155 (77-303) pg/ml v 31 (0-100) pg/ml, p<0.001) and (1.21 (0.91-1.88) pg/ml v 0.84 (0.67-1.13) pg/ml, p<0.01), respectively. Baseline concentrations of IL-8, ET-1, and VEGF were significantly related to the baseline HRCT fibrosis score (r = 0.42, p<0.005; r = 0.39, p<0.01; and r = 0.42, p<0.005, respectively). Patients with IIP who developed progressive disease had significantly higher baseline levels of IL-8 (345 (270-497) pg/ml v 121 (73-266) pg/ml, p = 0.001) and VEGF (1048 (666-2149) pg/ml v 658 (438-837) pg/ml, p = 0.019). Over 6 months the change in VEGF was significantly related to the change in HRCT fibrosis score (r = 0.565, p = 0.035) and negatively related to the change in forced vital capacity (r = -0.353, p = 0.035).
BACKGROUND: Angiogenesis has been implicated in the pathogenesis of idiopathic interstitial pneumonia (IIP). The aim of this study was to examine the relationship between plasma concentrations of the angiogenic cytokines interleukin 8 (IL-8), vascular endothelial growth factor (VEGF), and endothelin-1 (ET-1) and clinical parameters of disease progression over a 6 month period to identify potential aetiological mediators and prognostic markers of disease activity in patients with IIP. METHODS: Forty nine patients with IIP (40 men) were recruited to the study. Plasma cytokine measurements, pulmonary function tests, and high resolution computed tomography (HRCT) scans were performed on recruitment and after 6 months. Plasma cytokine measurements were also performed in 15 healthy volunteers for control purposes. RESULTS:Patients with IIP had significantly higher median (IQR) baseline concentrations of IL-8 and ET-1 than controls (155 (77-303) pg/ml v 31 (0-100) pg/ml, p<0.001) and (1.21 (0.91-1.88) pg/ml v 0.84 (0.67-1.13) pg/ml, p<0.01), respectively. Baseline concentrations of IL-8, ET-1, and VEGF were significantly related to the baseline HRCT fibrosis score (r = 0.42, p<0.005; r = 0.39, p<0.01; and r = 0.42, p<0.005, respectively). Patients with IIP who developed progressive disease had significantly higher baseline levels of IL-8 (345 (270-497) pg/ml v 121 (73-266) pg/ml, p = 0.001) and VEGF (1048 (666-2149) pg/ml v 658 (438-837) pg/ml, p = 0.019). Over 6 months the change in VEGF was significantly related to the change in HRCT fibrosis score (r = 0.565, p = 0.035) and negatively related to the change in forced vital capacity (r = -0.353, p = 0.035).
Authors: S E Gay; E A Kazerooni; G B Toews; J P Lynch; B H Gross; P N Cascade; D L Spizarny; A Flint; M A Schork; R I Whyte; J Popovich; R Hyzy; F J Martinez Journal: Am J Respir Crit Care Med Date: 1998-04 Impact factor: 21.405
Authors: E A Kazerooni; F J Martinez; A Flint; D A Jamadar; B H Gross; D L Spizarny; P N Cascade; R I Whyte; J P Lynch; G Toews Journal: AJR Am J Roentgenol Date: 1997-10 Impact factor: 3.959
Authors: M P Keane; D A Arenberg; J P Lynch; R I Whyte; M D Iannettoni; M D Burdick; C A Wilke; S B Morris; M C Glass; B DiGiovine; S L Kunkel; R M Strieter Journal: J Immunol Date: 1997-08-01 Impact factor: 5.422
Authors: J A Bjoraker; J H Ryu; M K Edwin; J L Myers; H D Tazelaar; D R Schroeder; K P Offord Journal: Am J Respir Crit Care Med Date: 1998-01 Impact factor: 21.405
Authors: Lesley Ann Saketkoo; Dana P Ascherman; Vincent Cottin; Lisa Christopher-Stine; Sonye K Danoff; Chester V Oddis Journal: Curr Rheumatol Rev Date: 2010-05
Authors: Yogesh M Kulkarni; Sucharita Dutta; Anand Krishnan V Iyer; Rajkumar Venkatadri; Vivek Kaushik; Vani Ramesh; Clayton A Wright; Oliver John Semmes; Juan S Yakisich; Neelam Azad Journal: Proteomics Date: 2015-11-24 Impact factor: 3.984
Authors: Tadeusz M Zielonka; Urszula Demkow; Dorota Michalowska-Mitczuk; Malgorzata Filewska; Beata Bialas; Katarzyna Zycinska; Michael H Obrowski; Jan Kus; Ewa Skopinska-Rozewska Journal: Lung Date: 2011-05-21 Impact factor: 2.584
Authors: Christian Stockmann; Yann Kerdiles; Marc Nomaksteinsky; Alexander Weidemann; Norihiko Takeda; Andrew Doedens; Antonio X Torres-Collado; Luisa Iruela-Arispe; Victor Nizet; Randall S Johnson Journal: Proc Natl Acad Sci U S A Date: 2010-02-08 Impact factor: 11.205
Authors: Stavros Garantziotis; Enrique Zudaire; Carol S Trempus; John W Hollingsworth; Dianhua Jiang; Lisa H Lancaster; Elizabeth Richardson; Lisheng Zhuo; Frank Cuttitta; Kevin K Brown; Paul W Noble; Koji Kimata; David A Schwartz Journal: Am J Respir Crit Care Med Date: 2008-08-14 Impact factor: 21.405